A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)

Marit Ahrens,Bernard Escudier,Ekaterini Boleti,Marc-Oliver Grimm,Marine Gross Goupir,Pilippe Barthelemy,Gwenaelle Gravis,Jens Bedekes,Philipp Ivanyi,Andrej Panic,Stefanie Zschaebitz,Sylvie Neyrieru,Begoña Mellado,Anika Biel,Tom Wadell,Jose Pablo Maroto,Margitta Retz,Martin Boegemann,Sylvie Rottey,John B. A. G. Haanen,Sjoukje F. Oosting,Daniel Castellano,Arndt Hartmann,Lothar Bergmann

A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)

2020

TPS5103Background: Non-clear cell renal cell carcinomas (nccRCC) are a heterogeneous group of tumors accounting for approximately 25% of RCC patients (pts.). Since most clinical trials focus on cle...

Keywords:

Phases of clinical research
Pathology
standard of care
Medicine
Clear cell renal cell carcinoma
Ipilimumab
Nivolumab
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations